Macular function following intravitreal ranibizumab for macular edema associated with branch retinal vein occlusion: 12-month results.
Aged
Aged, 80 and over
Angiogenesis Inhibitors
/ therapeutic use
Color Vision
/ physiology
Electroretinography
Female
Fluorescein Angiography
Humans
Intravitreal Injections
Macula Lutea
/ physiopathology
Macular Edema
/ drug therapy
Male
Middle Aged
Ranibizumab
/ therapeutic use
Retinal Vein Occlusion
/ drug therapy
Tomography, Optical Coherence
/ methods
Vascular Endothelial Growth Factor A
/ antagonists & inhibitors
Visual Acuity
/ physiology
BRVO
Focal macular ERG
Macular edema
Macular function
Ranibizumab
Journal
Documenta ophthalmologica. Advances in ophthalmology
ISSN: 1573-2622
Titre abrégé: Doc Ophthalmol
Pays: Netherlands
ID NLM: 0370667
Informations de publication
Date de publication:
10 2020
10 2020
Historique:
received:
17
07
2019
accepted:
11
02
2020
pubmed:
27
2
2020
medline:
10
10
2020
entrez:
27
2
2020
Statut:
ppublish
Résumé
To evaluate the 12-month effects of intravitral ranibizumab (IVR) injections on the physiology and morphology of the macula in eyes with a branch retinal vein occlusion with macular edema (BRVOME). We studied 13 eyes of 13 patients with a BRVOME. All patients were initially treated with IVR injections at 3 consecutive monthly intervals, the initiation phase. Additional treatments were done according to the pro re nata (PRN) regimen. The physiology of the macula was assessed by the focal macular electroretinograms (fmERGs) and the best-corrected visual acuity (BCVA). The morphology of the macular area was determined by spectral-domain optical coherence tomography. The retina was assessed at the baseline, and at 3, 6, and 12 months after beginning the IVR injections. The fmERGs were elicited by a 15° circular stimulus, and also by 15° semicircular stimuli placed on the occluded or non-occluded side of the macula. The amplitudes of the a- and b-waves, photopic negative response (PhNR), and sums of the oscillatory potentials (ΣOPs) were measured. In addition, the implicit times of the a- and b-waves were measured. The BCVA was improved significantly relative to the baseline after the initiation phase (P < 0.01), and it was maintained with the PRN regimen for the 12-month experimental period. The foveal thickness was also significantly decreased after the initiation phase (P < 0.005) but was then worse at 12 months during the maintenance phase (P < 0.05). The fmERGs on the occluded side were significantly reduced at the baseline, and the b-waves and ΣOPs amplitudes improved after the initiation phase. However, they decreased during the PRN period. On the non-occluded side, the amplitudes and implicit times of the a- and b-waves remained unchanged after the initiation phase, the PhNR and ΣOPs amplitudes significantly increased at 3 months compared to the baseline (PhNR, P < 0.005; ΣOPs, P < 0.005), which was maintained throughout the 12 month study period. The deterioration of the macular function on the occluded side during the maintenance phase suggests that there is a progression of the disease process during the PRN period in eyes with BRVOME.
Identifiants
pubmed: 32100140
doi: 10.1007/s10633-020-09757-0
pii: 10.1007/s10633-020-09757-0
doi:
Substances chimiques
Angiogenesis Inhibitors
0
VEGFA protein, human
0
Vascular Endothelial Growth Factor A
0
Ranibizumab
ZL1R02VT79
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
127-136Subventions
Organisme : Japan Society for the Promotion of Science
ID : 18K09420
Pays : International